피임 시장 : 제품 유형, 작용 기전, 소재 유형, 유효 기간, 사용 빈도, 판매 채널, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Contraceptive Market is projected to grow by USD 69.02 billion at a CAGR of 7.67% by 2032.

Contraceptive Executive Summary

The contraceptive landscape is a high-impact segment of women's health, reproductive medicine, consumer health, and public health policy. Demand is supported by measurable global need: the World Health Organization reports that roughly 1.1 billion women of reproductive age need family planning, including about 874 million using modern contraceptive methods and about 164 million with an unmet need.

For industry leaders, contraception is no longer limited to oral contraceptive pills. The category spans condoms, intrauterine devices, implants, injectables, emergency contraception, vaginal rings, patches, fertility-awareness tools, and digital contraceptive platforms. Opportunities are strongest where access, affordability, counseling quality, product choice, privacy, and supply-chain reliability align with evidence-based reproductive health needs.

Transformative Shifts in the Contraceptive Landscape

The contraceptive landscape is shifting from a product-centric model to a broader reproductive health ecosystem. Consumers and health systems increasingly prioritize method choice, side-effect management, non-daily options, over-the-counter availability, discreet access, and integrated counseling. Long-acting reversible contraceptives remain important because of high effectiveness, while condoms continue to play a dual role in pregnancy prevention and sexually transmitted infection reduction.

Policy is also reshaping the category. Expanded insurance coverage, public procurement, telehealth prescribing, pharmacist-led access, and self-care models are improving reach in many countries. At the same time, regulatory scrutiny, misinformation, cultural barriers, and inconsistent funding continue to influence adoption, continuation, and equitable access to contraceptive care.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is beginning to influence contraception through demand forecasting, inventory optimization, patient education, clinical decision support, and pharmacovigilance. AI-enabled analytics can help public programs reduce stockouts, identify service gaps, and tailor outreach to populations with documented unmet need.

The highest-value applications are likely to be responsible AI tools that support counseling without replacing clinicians. Algorithms can help personalize method discussions around medical eligibility, adherence preferences, side-effect concerns, and follow-up needs. However, deployment must address bias, privacy, reproductive autonomy, cybersecurity, and transparency, especially because contraceptive decisions involve sensitive health and personal data.

Key Regional Insights

Asia-Pacific is central to global contraceptive demand because of its population scale, urbanization, and large reproductive-age cohort. China and India anchor regional volume through extensive public health systems and domestic production capacity, while Japan, South Korea, Australia, and ASEAN markets show distinct adoption patterns shaped by fertility trends, clinical guidelines, private care access, and awareness of long-acting reversible contraception. North America remains a high-value region supported by reimbursement mechanisms, product innovation, telehealth infrastructure, and established clinical pathways, although access varies by state, province, payer, and income level.

Latin America has broad public-sector family planning programs and strong demand for injectables, implants, condoms, and oral contraceptives, but access gaps persist in rural, adolescent, Indigenous, and low-income communities. Europe is characterized by mature contraceptive use, national health systems, and strong regulatory oversight, with increasing attention to hormone-related concerns, method choice, affordability, and counseling standards. In the Middle East, contraceptive uptake is influenced by physician-led care, privacy expectations, and culturally aligned reproductive health services, while Africa remains closely linked to public health investment, donor procurement, supply-chain resilience, youth-friendly services, and community-based counseling to address documented unmet need.

Key Group Insights

Within ASEAN, contraceptive access is shaped by a mix of public programs, private pharmacies, community health services, and rising digital health use, with Indonesia, the Philippines, Vietnam, Thailand, and Malaysia representing diverse policy, religious, and cultural environments. The GCC combines high health spending with conservative social norms, creating demand for discreet, physician-guided, and culturally aligned reproductive health services that emphasize privacy and clinical trust.

The European Union offers a mature regulatory and reimbursement environment where safety monitoring, pharmacovigilance, adolescent access, and equitable affordability are central policy themes. BRICS countries are strategically important because Brazil, Russia, India, China, and South Africa combine large reproductive-age populations with different public procurement models, domestic manufacturing capabilities, and regional access gaps. G7 markets influence innovation, clinical standards, regulatory expectations, and premium product adoption, while NATO countries overlap substantially with advanced health systems where supply security, essential medicine availability, and resilient procurement are increasingly policy priorities.

Key Country Insights

The United States is shaped by insurance coverage, reproductive health policy, telehealth, pharmacist access, and over-the-counter contraception pathways, while Canada is expanding affordability through provincial and federal coverage initiatives. Mexico and Brazil rely on a mix of public-sector programs and private pharmacy access, with demand supported by large reproductive-age populations and ongoing needs for adolescent and rural access. In Europe, the United Kingdom, Germany, France, Italy, and Spain are mature markets where reimbursement, prescribing norms, primary-care access, and counseling quality affect method mix, while Russia has distinctive demographic priorities and meaningful private-sector demand.

In Asia-Pacific, China and India are scale markets where public health priorities, domestic production, urban-rural disparities, and regional access gaps shape contraceptive adoption. Japan has historically lower uptake of some hormonal methods compared with Western markets and continues to be influenced by physician prescribing practices and consumer attitudes toward hormones. Australia has strong primary-care access, reimbursement support, and high awareness of long-acting options. South Korea reflects advanced digital health adoption, urban access, and shifting fertility behavior, making it relevant for integrated reproductive health innovation.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based product portfolios that include short-acting, long-acting, non-hormonal, emergency, and barrier methods. The strongest strategies will pair clinical effectiveness with consumer experience, including side-effect transparency, affordability, discreet distribution, culturally competent counseling, and follow-up support.

Organizations should invest in supply-chain resilience, responsible digital tools, pharmacovigilance, provider education, and partnerships with public health agencies. In lower-access markets, success depends on training providers, reducing stockouts, supporting youth-friendly services, expanding last-mile distribution, and aligning with WHO medical eligibility guidance and national family planning priorities.

Research Methodology

The executive summary is based on a structured review of verified public health and industry evidence from organizations such as the World Health Organization, United Nations agencies, the Guttmacher Institute, national health authorities, and peer-reviewed reproductive health literature.

The analysis emphasizes contraceptive prevalence, unmet need, method mix, policy access, reimbursement, regional health-system structure, supply-chain reliability, and technology adoption. Claims are limited to established trends and data-backed insights, avoiding unsupported market-size, market-share, or forecasting assumptions.

Conclusion

Contraception is an essential health category with measurable benefits for maternal health, education, workforce participation, and economic resilience. The industry's next phase will be defined by broader access, expanded method choice, safer counseling, digital enablement, responsible AI adoption, and reliable supply.

Leaders that combine scientific credibility, consumer trust, equitable pricing, privacy protection, and strong distribution will be best positioned. The most durable opportunities will come from serving both mature markets seeking convenience and emerging markets still working to close documented unmet need.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Contraceptive Market, by Product Type

• 7.1. Contraceptive Drugs
  • 7.1.1. Oral Contraceptive Pills
  • 7.1.2. Emergency Contraceptive Pills
  • 7.1.3. Injectable Contraceptives
• 7.2. Contraceptive Devices
  • 7.2.1. Intrauterine Devices (IUDs)
    • 7.2.1.1. Hormonal IUDs
    • 7.2.1.2. Copper IUDs
  • 7.2.2. Subdermal Implants
  • 7.2.3. Vaginal Rings
  • 7.2.4. Contraceptive Patches
• 7.3. Barrier Methods
  • 7.3.1. Male Condoms
  • 7.3.2. Female Condoms
  • 7.3.3. Diaphragms
  • 7.3.4. Cervical Caps
• 7.4. Permanent Methods
  • 7.4.1. Tubal Ligation
  • 7.4.2. Vasectomy

8. Contraceptive Market, by Mode Of Action

• 8.1. Prevent Implantation
• 8.2. Spermicidal Action
• 8.3. Suppress Ovulation

9. Contraceptive Market, by Material Type

• 9.1. Latex-Based
• 9.2. Non-Latex
  • 9.2.1. Nitrile
  • 9.2.2. Polyisoprene
  • 9.2.3. Polyurethane

10. Contraceptive Market, by Duration

• 10.1. Long-Term
• 10.2. Short-Term

11. Contraceptive Market, by Usage Frequency

• 11.1. On-Demand
• 11.2. Regular Use

12. Contraceptive Market, by Sales Channel

• 12.1. Offline
  • 12.1.1. Hospital Pharmacy
  • 12.1.2. Pharmacy
• 12.2. Online
  • 12.2.1. E-Commerce Platforms
  • 12.2.2. Online Pharmacy

13. Contraceptive Market, by Application

• 13.1. General Use
• 13.2. Post-Coital Use

14. Contraceptive Market, by End-User

• 14.1. Female
  • 14.1.1. Adolescent
  • 14.1.2. Adult
  • 14.1.3. Post-Menopausal
• 14.2. Male

15. Contraceptive Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Contraceptive Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Contraceptive Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. AbbVie Inc.
• 19.2. Afaxys, Inc.
• 19.3. Agile Therapeutics, Inc.
• 19.4. Allergan plc
• 19.5. Bayer AG
• 19.6. Church & Dwight Co., Inc.
• 19.7. Cipla Limited
• 19.8. CooperSurgical, Inc.
• 19.9. DKT International
• 19.10. Dr. Reddy's Laboratories Ltd.
• 19.11. Famy Care Ltd.
• 19.12. GlaxoSmithKline plc
• 19.13. Glenmark Pharmaceuticals Ltd.
• 19.14. HLL Lifecare Limited
• 19.15. Johnson & Johnson
• 19.16. Karex Berhad
• 19.17. Lupin Limited
• 19.18. Merck & Co., Inc.
• 19.19. Mylan N.V.
• 19.20. Novartis AG
• 19.21. Organon & Co.
• 19.22. Pfizer Inc.
• 19.23. Piramal Pharma Limited
• 19.24. Pregna International Limited
• 19.25. Reckitt Benckiser Group plc
• 19.26. Shanghai Dahua Pharmaceutical Co., Ltd.
• 19.27. Sun Pharmaceutical Industries Ltd.
• 19.28. Teva Pharmaceutical Industries Ltd.
• 19.29. The Cooper Companies, Inc.
• 19.30. Viatris Inc.